Company news

Suzhou Zelgen Biopharmaceuticals Co. Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Announcement on Using Self-owned Funds to Pay Funds Required for Investment Projects Financed by Raised Funds and Replacing Them with an Equal Amount of Raised Funds

August 22, 2025

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 Injectable ZGGS18 and Gecacitinib Hydrochloride Tablets

August 21, 2025

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 and Gecacitinib Hydrochloride Tablets with Chemotherapy Regimen

August 20, 2025

Announcement on Voluntary Disclosure of Obtaining FDA Approval for the Clinical Trial of ZGGS34 for Injection

August 19, 2025

Announcement on Voluntary Disclosure of Inclusion of ZG006 for Injection Being Included in the List of Drugs Granted Breakthrough Therapy Designation

July 10, 2025

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Injectable ZG006

June 17, 2025

Announcement on Voluntary Disclosure and Signing of Exclusive Marketing Service Agreement for Recombinant Human Thyroid Stimulating Hormone for Injection

June 5, 2025

Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG006 and ZG005 Released at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 2, 2025

Announcement on the Approval of Gecacitinib Hydrochloride Tablets for Marketing

May 29, 2025

Announcement on Using Some Temporarily Idle Raised Funds for Cash Management

May 16, 2025

Announcement on Voluntary Disclosure of Acceptance of New Drug Marketing Application for Treatment of Severe Alopecia Areata with Gecacitinib Hydrochloride Tablets

May 13, 2025

Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing

April 24, 2025

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials for the Combination of ZG006 for Injection with PD-1/PD-L1 Immune Checkpoint Inhibitor

April 20, 2025

Announcement on Subproject Change, Amount Adjustment, and New Subprojects of Some Investment Projects Financed by Raised Funds

April 18, 2025

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Chemotherapy Regimen

April 9, 2025

Announcement on Preliminary Earnings Estimate for 2024

February 26, 2025

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Platinum-based Chemotherapy Regimen

February 17, 2025

Indicative Announcement on the Renewal of Concerted Action Agreement and Changes in Equity by Actual Controllers

January 23, 2025

Annual Earnings Preannouncement for 2024

January 17, 2025

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Gecacitinib Hydrochloride Tablets

December 25, 2024

Announcement on Voluntary Disclosure of Inclusion of Recombinant Human Thrombin into the Catalogue Of Drugs For Basic National Medical Insurance in 2024

November 28, 2024

Announcement on Convening the Q3 2024 Performance Briefing

November 22, 2024

Announcement on Cancelling Some Special Accounts for Raised Funds

October 28, 2024

Announcement on Postponement of Some Investment Projects Financed by Raised Funds

October 25, 2024

Announcement on Voluntary Disclosure of Clinical Study Progress of ZG005 for Injection

September 25, 2024

Announcement on Voluntary Disclosure of Clinical Study Progress of ZG006 for Injection

September 8, 2024

Announcement on Attending the 2024 Semi-annual Collective Performance Briefing for Pharmaceutical and Biological Products Companies on STAR Market

September 6, 2024

Announcement on Resolutions of the 15th Meeting of the 2nd Board of Supervisors

August 23, 2024

Announcement on Voluntary Disclosure of Notice on Registration and Clinical Verification of Recombinant Human Thyrotropin for Injection

August 12, 2024

← Newer news releases